With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6624-49-3,Isoquinoline-3-carboxylic acid,as a common compound, the synthetic route is as follows.
6624-49-3, General procedure: To a mixture of A-b (100 mg, 0.43 mmol), acid (0.51 mmol), HATU (241 mg, 0.64 mmol) and DIPEA (109 mg, 0.85 mmol) in DMF (3 mL) was stirred at 25 C for 16 h. The mixture was diluted by the addition of water (20 mL). General Work-up Procedure 1 was followed. The residue was purified by prep-HPLC or Chromatography to afford the title compound. Followed General procedure 3 to afford 8b (126 mg, 20%). MS (ESI) calc?d for (C2IH19N5OS) [M+Hf, 390.1; found, 390.0. NMR (300 MHz, DMSO-r/6) d 10.77 (s, 1H), 9.48 (s, 1H), 8.72 (s, 1H), 8.55 (s, 1H), 8.33 – 8.24 (m, 2H), 8.00 – 7.83 (m, 4H), 7.34 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 7.8 Hz, 1H), 4.70 (q, .7 = 6.9 Hz, 1H), 3.42 (s, 3H), 1.69 (d, .7 = 6.9 Hz, 3H).
As the paragraph descriping shows that 6624-49-3 is playing an increasingly important role.
Reference£º
Patent; NURIX THERAPEUTICS, INC.; BARSANTI, Paul A.; BENCE, Neil F.; GOSLING, Jennifa; SAHA, Anjanabha; TAHERBHOY, Asad M.; ZAPF, Christoph W.; BOYLE, Kathleen; CARDOZO, Mario; MIHALIC, Jeffrey; LAWRENZ, Morgan; GALLOP, Mark; BRUFFEY, Jilliane; CUMMINS, Thomas; ROBBINS, Daniel; TANAKA, Hiroko; WANG, Chenbo; COHEN, Frederick; PALMER, Wylie; SANDS, Arthur T.; SHUNATONA, Hunter; (968 pag.)WO2019/148005; (2019); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem